Value of fecal calprotectin in the diagnosis of chronic inflammatory bowel diseases in children
Background. Inflammatory bowel diseases are considered to be one of the most difficult problems of children gastroenterology, which have not only medical but also social significance. Recently, a lot of attention has been paid to non-invasive diagnostic methods such as fecal markers of inflammation in chronic inflammatory bowel diseases. The aim of the research was to study the diagnostic value of fecal calprotectin in chronic bowel diseases in children. Materials and methods. We have examined 19 patients aged 3 to 17 years in the active phase of chronic inflammatory bowel diseases (ulcerative colitis and non-specific non-ulcerative colitis). The comparison group included 12 children with irritable bowel syndrome. In addition to standard examination methods, we have studied the level of calprotectin in fecal samples using monoclonal antibodies. Results. According to the data of our research, in patients with chronic inflammatory bowel diseases, the average level of calprotectin in feces 3 times exceeded the normal values, and since patients were examined in the active phase of chronic inflammatory bowel diseases, the fecal calprotectin level was increased in all of them. The level of fecal calprotectin was significantly higher in patients with ulcerative colitis in comparison with those with non-specific non-ulcerative colitis. In functional disease — irritable bowel syndrome, the level of fecal calprotectin did not exceed the normal values in any of the patients. Conclusions. The study of fecal calprotectin level in chronic inflammatory bowel diseases in children has high diagnostic value as a screening for the exclusion of the organic nature of bowel disease and determination of indications for using instrumental diagnostic methods. The implementation of non-invasive technique to evaluate calprotectin in fecal samples in children with intestinal pathology will allow monitoring the dynamic course of the chronic inflammatory bowel diseases in children, assessing the results of the therapy, and reducing the number of invasive methods of examination.
Full Text:PDF (Русский)
Stepanov YuM, Skyrda IYu, Petishko OP. Chronic inflammatory bowel diseases: epidemiological features in Ukraine. Gastroenterologìa. 2017;51(2):97-105. doi: 10.22141/2308-2097.51.2.2017.101703. (in Russian).
Belousova EA. Iazvennyi kolit i bolezn' Krona [Ulcerative colitis and Crohn's disease.]. Tver: Triada; 2002.128 p. (in Russian).
Khalif IL, Loranskaia ID. Vospalitel'nye zabolevaniia kishechnika (nespetsificheskii iazvennyi kolit i bolezn' Krona). Klinika, diagnostika i lechenie [Inflammatory bowel disease (nonspecific ulcerative colitis and Crohn's disease). Clinic, diagnosis and treatment]. Moscow: Miklosh; 2004. 88 p. (in Russian).
Maev IV, Kucheriavyi IuA, Cheremushkin SV. Evoliutsiia predstavlenii o sindrome razdrazhennogo kishechnika [Evolution of ideas about irritable bowel syndrome]. Moscow: Forte-print; 2013. 80 p. (in Russian).
Pavlenko NV, Voloshyn KV, Ganzij OB, Slobodjanjuk OL. Determination of intestine inflammation markers in diagnostic search in children with intestinal diseases. Zdorovʹe rebenka. 2016;5(73):47-50. doi:10.22141/2224-0522.214.171.124.1.2016.78940. (іn Ukrainian).
Stepanov YuM, Psareva IV. The role of biomarkers in the diagnostics of chronic inflammatory bowel diseases. Gastroenterologìa. 2017;1(51):56-63. doi: 10.22141/2308-2097.51.1.2017.97872. (іn Ukrainian).
Otten CM, Kok L, Witteman BJ, et al. Diagnostic performance of rapid tests for detection of fecal calprotectin and lactoferrin and their ability to discriminate inflammatory from irritable bower syndrome. Clin Chem Lab Med. 2008;46(9):1275-80. doi: 10.1515/CCLM.2008.246.
Peterson CG, Sangfelt P, Wagner M, Hansson T, Lettesjö H, Carlson M. Fecal levels of leukocyte markers reflect disease activity in patients with ulcerative colitis. Scand J Clin Lab Invest. 2007;67(8):810-20. doi: 10.1080/00365510701452838.
Wagner M, Peterson CG, Ridefelt P, Sangfelt P, Carlson M. Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease. World J Gastroenterol. 2008 Sep;14(36):5584-5589. PMID: 18810778.
- There are currently no refbacks.
Copyright (c) 2018 CHILD`S HEALTH
This work is licensed under a Creative Commons Attribution 4.0 International License.
© Publishing House Zaslavsky, 1997-2018